Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Targeted Therapies Patient Forum September 2017 Speaker Highlight - John Cherol
Author
Denise Brock

***Speaker Highlights***

for full faculty bio's, please visit our FACULTY page


 Learn about John Cherol, EGFR patient

 

*** update - John sadly passed away in January of 2018 at the very young age of 30. Our hearts are heavy with sadness.  Condolences to his loving family. https://www.waskofamily.com/notices/John-Cherol***

 

John Cherol was diagnosed in January 2016 with Stage IV EGFR+ lung cancer at the age of 28. He started Gilotrif (afatinib) and acquired resistance after 14 months. Luckily a blood test showed he developed the t790m mutation and he started Tagrisso in April of this year. He’s also been treated for nine brain mets with Gamma Knife at the Cleveland Clinic.

John is a graduate of Youngstown State University with a bachelor’s degree in computer forensics.  He currently works as a Senior Cyber Security Analyst in Pittsburgh, PA. He got engaged shortly after his diagnosis to his fiancé, Kristine, who he met in 2014. They’re actively planning their September 9th wedding and a honeymoon to Iceland. Thanks to targeted therapy, John has been able to continue some of the hobbies he loves most like camping and kayaking. He hopes to help change the face of lung cancer and enjoy many more evening walks with Kristine and their rescue dog Liam.

 

 


 

 


 

 

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora